IP Library Granted Patent US 11,780,805
Granted Patent B2
US 11,780,805 · App. 17/470,063 · Granted Oct 10, 2023

Carbamoyl phenylalaninol compounds and uses thereof

Inventors: Fionn Hurley (Baldoyle, IE); Lawrence Patrick Carter (Palo Alto, CA)
Assignee: Axsome Malta Ltd.
C07C271/66C07C2601/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,780,805
App. No.
17/470,063
Granted
Oct 10, 2023
Kind
B2
Abstract

The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.

Claims (25)

1. A method of treating narcolepsy, cataplexy, excessive daytime sleepiness, drug addiction, sexual dysfunction, fatigue, fibromyalgia, restless legs syndrome, depression, bipolar disorder, or obesity in a subject in need thereof, or promoting smoking cessation in a subject in need thereof, comprising administering to the subject compound 1:

or a pharmaceutically acceptable salt thereof.

2. A method of inducing a pro-cognitive effect in a subject in need thereof, comprising administering to the subject compound 1:

or a pharmaceutically acceptable salt thereof;

wherein the subject has bipolar depression, major depressive disorder, PTSD, or Parkinson's Disease.

3. A method of treating nightmares and/or sleep-related disturbances associated with PTSD in a subject in need thereof, comprising administering to the subject compound 1:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is compound 2:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , comprising administering a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.

6. The method of claim 5 , wherein the composition is a dosage form.

7. The method of claim 6 , wherein the composition is an immediate release oral dosage form.

8. The method of claim 7 , wherein the composition is a tablet or a capsule.

9. The method of claim 2 , wherein the compound is compound 2:

or a pharmaceutically acceptable salt thereof.

10. The method of claim 2 , comprising administering a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.

11. The method of claim 10 , wherein the composition is a dosage form.

12. The method of claim 11 , wherein the composition is an immediate release oral dosage form.

13. The method of claim 12 , wherein the composition is a tablet or a capsule.

14. The method of claim 3 , wherein the compound is compound 2:

or a pharmaceutically acceptable salt thereof.

15. The method of claim 3 , comprising administering a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.

16. The method of claim 15 , wherein the composition is a dosage form.

17. The method of claim 16 , wherein the composition is an immediate release oral dosage form.

18. The method of claim 17 , wherein the composition is a tablet or a capsule.

Assignments (3)
SECURITY INTEREST Recorded May 9, 2025
From: AXSOME THERAPEUTICS, INC.; AXSOME MALTA LTD.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 071247/0836 →
SECURITY INTEREST Recorded Sep 9, 2024
From: AXSOME MALTA LTD
To: HERCULES CAPITAL, INC.
Reel/Frame 068900/0023 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2022
From: JAZZ PHARMACEUTICALS IRELAND LIMITED
To: AXSOME MALTA LTD.
Reel/Frame 060223/0878 →